BioLineRx sells APHEXDA royalty rights for $5.6 million
BioLineRx (BLRX) sold 14.4% royalty rights to APHEXDA for $5.6M to Soleus Capital. The deal excludes 3.6% royalties. Proceeds will fund R&D, working capital, and partial loan repayment. The transaction is expected to close by November 30, 2026. APHEXDA is an FDA-approved drug for stem cell mobilization in multiple myeloma. BioLineRx is also developing GLIX1 for glioblastoma.
How this was made
The 30-second read
Why it matters
The transaction converts a portion of future royalty receipts into upfront cash, intended to fund GLIX1 clinical development and working capital, and it removes a $4 million minimum cash balance requirement under a related loan agreement.
Market read
Traders may reassess BioLineRx’s near-term liquidity, debt covenant flexibility, and the trade-off between upfront funding and reduced future royalty participation.
What to watch
The article notes BioLineRx retains milestone payments and pre-closing royalties, so the net economic impact depends on expected future sales trajectory and the remaining 3.6% royalty exclusion mechanics.
Background
BioLineRx has a royalty interest in APHEXDA under an existing license agreement with Ayrmid Pharma; APHEXDA is FDA-approved for mobilizing hematopoietic stem cells in multiple myeloma.
Ticker impact
BioLineRx will sell its 14.4% APHEXDA royalty interest for a one-time $5.6 million, shifting future cash flows and funding R&D.
Likely modest positive bias on liquidity, partially offset by reduced future royalty economics.
The deal is specific (14.4% interest, $5.6M, closing around Nov 30, 2026) and tied to stated use of proceeds, but it is not a full exit and the amount is relatively small versus typical biotech valuations.
Market effects
Highlights a broader biotech financing pattern of monetizing royalty streams to fund clinical programs.
Limited direct regional spillover; transaction is company-specific and tied to a US-approved product.
APHEXDA commercialization is global (with Asia partnership), but the news mainly affects BioLineRx’s capital structure and cash-flow profile.
Counterpoint
The $5.6M monetization could be viewed as selling upside too cheaply if APHEXDA royalty economics improve materially after commercialization ramps.
Key entities
- companyBioLineRx Ltd.
NASDAQ-listed biotech selling part of its APHEXDA royalty rights to Soleus Capital for $5.6M.
- counterpartySoleus Capital Management, L.P.
Acquirer of BioLineRx’s 14.4% royalty interest in future net sales of APHEXDA.
- productAPHEXDA
FDA-approved CXCR4 antagonist used with filgrastim for stem cell mobilization in multiple myeloma.
- counterpartyAyrmid Pharma Ltd.
Holds the existing license agreement under which APHEXDA royalties are owed to BioLineRx.
- pipeline assetGLIX1
BioLineRx Phase 1/2a glioblastoma and other solid tumors program currently enrolling the fourth of five dosing cohorts.

